Arcadia Biosciences (NASDAQ:RKDA) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a report published on Friday. The brokerage issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and set a $6.00 price target on shares of Arcadia Biosciences in a report on Wednesday, August 21st.

Arcadia Biosciences Stock Performance

RKDA stock opened at $2.93 on Friday. The stock’s 50 day simple moving average is $2.85 and its 200 day simple moving average is $2.67. Arcadia Biosciences has a 12-month low of $1.85 and a 12-month high of $4.19. The stock has a market capitalization of $3.98 million, a PE ratio of -0.57 and a beta of 1.34.

Arcadia Biosciences (NASDAQ:RKDA) last posted its quarterly earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing the consensus estimate of $1.27 by ($0.49). Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. The business had revenue of $1.31 million during the quarter, compared to analysts’ expectations of $0.95 million. During the same quarter in the prior year, the firm earned ($2.64) EPS. On average, research analysts predict that Arcadia Biosciences will post -1.7 earnings per share for the current year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.